theravance.com - רווח החברה לפני מסים, ריבית ופחת TBPH

Geopolitical tensions and sanctions are hindering the export of respiratory treatments and the supply of raw materials. Theravance Biopharma (TBPH) reports these fluctuations in its EBITDA, where 8.02 indicates the value of this parameter. Partnerships with tech giants to secure royalties provide stability, while a strong R&D team ensures the development of unique medications.
Theravance Biopharma, Inc. - פילוחים אנליטיים ומדדי מפתח (TBPH)

Asset reliability is determined by a business's ability to generate real cash flow. Absolute operating profit measures actual cash from core activities before deducting depreciation and interest. For Theravance Biopharma (TBPH), this flow is generated through regular licensing royalties for inhalers. This inflow of funds offsets the costs of developing new drugs. Analyzing absolute operating profit allows for the distinction between sustainable income and accounting adjustments.